Global /Norway /Healthcare /Drug Manufacturers - General /VISTN

Vistin Pharma ASA

VISTN

• OSL: VISTN • Delayed

22.80NOK 0.4%

2.44 USD

As of 5 June 2026, Vistin Pharma ASA has a market cap of $108.47M USD, ranking #24964 globally and #151 in Norway. It ranks #2237 in the Healthcare sector, and #811 in the Drug Manufacturers - General industry.

Global Rank

24964

Country Rank

151

Sector Rank

2237

Industry Rank

811

Key Stats

Market Cap

$108.47MUSD

1.01B NOK

Enterprise Value

$107.57MUSD

1.01B NOK

Revenue (TTM)

$48.22MUSD

449.47M NOK

EBITDA (TTM)

$11.98MUSD

111.99M NOK

Net Income (TTM)

$8.0MUSD

74.55M NOK

EBITDA Margin

25%

Profit Margin

17%

PE Ratio

13.6

PS Ratio

2.2

PB Ratio

2.9

EV/EBITDA

9.0

Company Profile

Country (HQ)

Norway

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Magnus Tolleshaug open_in_new

Employees

Founded

1969

Website

vistin.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.4%	-0.9%	5.1%	7%	2.7%	9.6%	-5%	4.1%	-9.7%

News

Markets

Exchange	Ticker	Price	Quotes
Euronext Oslo Børs (OSL) MIC: XOSL PRIMARY	VISTN ISIN: NO0010734122 Shares Out.: Shares Outstanding: 44.345M¹ Shares Float: 16.796M² TV: TradingView: OSL: VISTN SA: Stock Analysis: OSL: VISTN YF: Yahoo Finance: VISTN.OL GF: Google Finance: OSL: VISTN BA: Barron's: VISTN MS: Morningstar: XOSL: VISTN	22.80 NOK	TV: TradingView: OSL: VISTN SA: Stock Analysis: OSL: VISTN YF: Yahoo Finance: VISTN.OL GF: Google Finance: OSL: VISTN BA: Barron's: VISTN MS: Morningstar: XOSL: VISTN
London Stock Exchange (LSE / LON) MIC: XLON	0RAM ISIN: NO0010734122 TV: TradingView: LSE: 0RAM SA: Stock Analysis: LON: 0RAM YF: Yahoo Finance: 0RAM.L GF: Google Finance: LON: 0RAM BA: Barron's: 0RAM MS: Morningstar: XLON: 0RAM	22.80 NOK	TV: TradingView: LSE: 0RAM SA: Stock Analysis: LON: 0RAM YF: Yahoo Finance: 0RAM.L GF: Google Finance: LON: 0RAM BA: Barron's: 0RAM MS: Morningstar: XLON: 0RAM
Nasdaq Stockholm (STO) MIC: XSTO	VISTINo (VISTNO) ISIN: NO0010734122 TV: TradingView: OMXSTO: VISTINo SA: Stock Analysis: STO: VISTINo YF: Yahoo Finance: VISTINo.ST GF: Google Finance: STO: VISTINo BA: Barron's: VISTINo MS: Morningstar: XSTO: VISTINo	22.90 NOK	TV: TradingView: OMXSTO: VISTINo SA: Stock Analysis: STO: VISTINo YF: Yahoo Finance: VISTINo.ST GF: Google Finance: STO: VISTINo BA: Barron's: VISTINo MS: Morningstar: XSTO: VISTINo

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Vistin Pharma ASA

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.

Similar Companies

Industry: Drug Manufacturers - General (Norway)

Name	Market Cap (USD) diff.	PE	Country
Nykode Therapeutics AS OSL: NYKD	$107.9M 1.01B NOK -0.5%	-	Norway
Lytix Biopharma ASA OSL: LYTIX	$84.15M 784.38M NOK -22%	-	Norway
Oncoinvent ASA OSL: ONCIN	$13.95M 130.0M NOK -87%	-	Norway
Arctic Bioscience AS OSL: ABS	$9.83M 91.65M NOK -91%	-	Norway

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 702K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 504K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 332K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 298K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 267K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 255K%	20.5	Switzerland

chevron_leftBack